TABLE 2

Antimicrobial susceptibility results for Achromobacter strains isolated from domestic environment samples and from the respiratory tracts of the 3 CF patientsa

StrainSample ID or patientSTResult (%) for antibiotic tested at indicated cutoff value (in mm)
AMX,19AMC,19PIP,18–21TPZ,18–21ATM,21–24TIC,15–20TCC,15–20FOX,15–19CTX,15–23CAZ,15–18FEP,15–18CF,16–23CPD,21IPM,17–23ETM,22–25MEM,15–21GM,17TM,17NET,16AKN,15–18FSF,13–16C,17TET,12–15CS,12NA,14–19OFX,19–22CIP,21LEV,18–21SXT,13–16
Environmental
    A. animicusP2-97360SSSSRSSRRSSRRSSSSSSSRSSSSSSSS
    A. mucicolensP12-61 (1)349SSSSRSSRSSSSRSSSSSSSRSSSSSSSS
P12-61 (2)349SSSSRSSRRSSSRSSSSSSSRSSSSSSSS
P12-61 (3)349SSSSRSSRSSSSRSSSSSSSRSSSSSSSS
P2-106353SSSSRSSRRSSSRSSSSRSSRSSSSSSSS
P12-49359SSSSRSSRRSSRRSSSSSSSRSSSSSSSS
P5-56355SSSSRSSRRSSSRSSSSSSSRSSSSSSSS
P5-74 (1)357SSSSRSSRSSSSRSSSSSSSRSSSSSSSS
P5-74 (2)358SSSSRSSRSSSSRSSSSSSSRSSSSSSSS
    A. aegrifaciensP2-20 (1)350SSSSRSSRRSSSRSSSSRSSRRRSSRSSS
P2-20 (2)350SSSSRSSRRSSSRSSSSRSSRRRSSSSSS
P12-26143SSSSRSSRRSSSRSSSRRRSRSSSSSSSS
    A. spaniusP2-101 (1)352SSSSRSSRRSSSRSSSSSSSRSSSSRSSS
P5-58356SSSSRSSRRSSSRSSSSSSSRSSSSRSSS
    A. marplatensisP5-11354SSSSRSSRSSSSRSSSSSSSRSSSSSSSS
    Achromobacter sp. gen. 9P2-101 (2)351SSSSRSSRRSSSRSSSSSSSRSSSSSSSS
    A. xylosoxidansP5-71175SSSSRSSRRSRRRSSSRRRRRSRSRRSSS
P5-64175SSSSRSSRRSSRRSSSRRRRRSRSSRSSS
P5-72175SSSSRSSRRSRRRSSSRRSSRSRSSRSSS
P5-50175SSSSRSSRRSSRRSSSRRRRRSRSSSSSS
P5-71169SSSSRSSRSSSSRSSSSSSSRSSSSSSSS
Patient
    A. xylosoxidansPatient 2328S (60)S (67)S (100)S (100)R (100)S (81)S (89)R (100)R (100)R (63)R (100)R (100)R (100)S (92)R (100)S (100)R (100)R (100)R (100)R (100)R (100)R (85)R (100)S (89)R (70)R (100)R (96)R (85)R (85)
Patient 527R (100)R (100)R (100)R (100)R (100)R (100)R (100)R (100)R (100)R (93)R (100)R (100)R (100)R (100)R (100)R (100)R (100)R (100)R (100)R (100)R (100)R (53)R (93)S (93)R (53)R (100)R (100)R (93)R (53)
Patient 12327S (75)R (62)S (100)S (100)R (100)S (100)S (100)R (100)R (100)R (50)R (100)R (100)R (100)S (100)R (100)S (75)R (100)R (100)R (100)R (100)R (100)S (63)R (100)S (62)R (75)R (100)R (100)R (100)S (75)
  • a Sample identification (ID) is composed of the patient number followed by the sample number. S, susceptible; R (in bold), resistant and intermediate. AMX, amoxicillin; AMC, amoxicillin-clavulanic acid; PIP, piperacillin; TPZ, piperacillin-tazobactam; ATM, aztreonam; TIC, ticarcillin; TCC, ticarcillin-clavulanic acid; FOX, cefoxitin; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; CF, cephalothin; CPD, cefpodoxime; IMP, imipenem; MEM, meropenem; GM, gentamicin; TM, tobramycin; NET, netilmicin; AKN, amikacin; FSF, fosfomycin; C, chloramphenicol; TET, tetracycline; CS, colistin; NA, nalidixic acid; OFX, ofloxacin; CIP, ciprofloxacin; LEV, levofloxacin; SXT, co-trimoxazole. Cutoff values were chosen as described by Dupont et al. (35); they consist of the susceptibility cutoff point edited for Acinetobacter by the Antibiogram Committee of the French Society for Microbiology in 2016 or, when not available, those edited for Enterobacteriaceae. For the 3 patients, the antibiogram result is a percentage of resistance or susceptibility obtained for the majority of the 27 colonies (P2), 15 colonies (P5), and 8 colonies (P12) isolated from the same sputum sample (35).